Is there a niche for zinc oxide nanoparticles in future drug discovery?

Erem Bilensoy,Cem Varan
DOI: https://doi.org/10.1080/17460441.2023.2230152
2023-06-29
Expert Opinion on Drug Discovery
Abstract:Zinc oxide (ZnO) exists in the nature as a mineral in the crust of the Earth and is the second most abundant mineral in the human body after iron. It has been recognized as GRAS (Generally Recognized as Safe) by FDA since ZnO nanoparticles >100 nm are considered biocompatible. ZnO is less toxic than other metal oxide nanoparticles such as Titanium dioxide (TiO 2) , is inexpensive, and does not react with most pharmaceutical active ingredients, contributing to its advantageous potential as drug delivery material [ Citation 1 ]. ZnO is luminescent, a semiconductor with a wide bandgap of excitation energy, and an alternative to Cadmium (Cd)-based imaging and therefore used to visualize tissues or cells besides its applications to electronics and optics. In fact, ZnO nanoparticles coated with Silicon dioxide (SiO 2 ) have been used as theranostic for imaging of cancer cells and delivery of anticancer molecule curcumin to these cells [ Citation 2 ].
pharmacology & pharmacy
What problem does this paper attempt to address?